Biotech Business - June 12, 2023
Novo Nordisk invests 15.9 billion DKK in expansion of manufacturing facilities
The company will invest 15.9 billion DKK starting in 2023 to expand an existing Active Pharmaceutical Ingredient (API) production facility in Denmark for the future portfolio within serious chronic diseases. The investment in Hillerød will create additional production capacity and increase Novo Nordisk’s ability to meet future market demands and be a key enabler for […]
Biotech Business - June 8, 2023
Mendus enters alliance with NorthX and announces a directed share issue
Mendus has entered into a manufacturing alliance with NorthX Biologics and has announced a directed share issue and a fully secured rights issue of units totaling approximately 317 million SEK in financing. In the alliance with NorthX, Mendus and NorthX will co-establish cell therapy manufacturing capabilities in Sweden, which will be used for late-stage development […]
Biotech Business - June 1, 2023
The Swedish Economic Crime Authority terminates investigation of Oncopeptide’s CSO
Oncopeptides has been informed that the preliminary investigation by the Swedish Economic Crime Authority of the company’s Chief Scientific Officer and former CEO, Jakob Lindberg, has been terminated. In their decision, the Swedish Economic Crime Authority writes that there is no longer a reason to complete the preliminary investigation as “the investigative material available [does […]
Biotech Business - May 30, 2023
Oculis listed on Nasdaq in New York
The Iceland-founded biopharmaceutical company was officially listed on the Nasdaq stock exchange in New York, making it the first Icelandic VC portfolio company to go public. Both Klappir and Solid Clouds were previously listed on the Nasdaq First North Growth Market in Iceland, but neither counted Icelandic VC’s as investors when going public. The same […]
Biotech Business - May 29, 2023
Alligator Bioscience receives FDA Orphan Drug Designation
The U.S. Food and Drug Administration has granted Orphan Drug Designation (ODD) to the company’s lead asset mitazalimab for the treatment of pancreatic cancer. “This designation is a key milestone for our lead asset mitazalimab, which is producing outstanding clinical results in its Phase 2 trial in pancreatic cancer,” says Søren Bregenholt, CEO of Alligator […]
Biotech Business - May 24, 2023
New Swedish innovation cluster for advanced therapies
On behalf of the Swedish government, the Swedish innovation agency Vinnova has decided on funding of an innovation cluster for commercialization, competence development and production capacity for advanced therapies. The new cluster will serve as a national infrastructure and competence node for the benefit of companies throughout the country and it will also strengthen Sweden’s […]
